Skip to main content
main-content

Connective tissue diseases

Medications

27-02-2019 | Systemic lupus erythematosus | News

Add-on belimumab efficacy maintained for up to 13 years in SLE patients

Individuals with systemic lupus erythematosus who respond to belimumab plus standard of care therapy can hope to experience long-term disease control, suggests a trial in which participants received treatment for up to 13 years.

Emerging therapies for lupus nephritis

Lupus nephritis is the most common organ-threatening complication of systemic lupus erythematosus, and current treatment regimens are only partially effective and are potentially toxic. In this editorial, the authors focus on emerging therapeutics to treat this disease.

29-01-2019 | Lupus nephritis | Editorial | Article

Emerging therapies for lupus nephritis

Lupus nephritis is the most common organ-threatening complication of systemic lupus erythematosus, and current treatment regimens are only partially effective and are potentially toxic. In this editorial, the authors focus on emerging therapeutics to treat this disease.

Add-on omalizumab shows potential for SLE

Preliminary results from a phase Ib trial suggest that add-on treatment with the anti-IgE antibody omalizumab may be a feasible option for patients with systemic lupus erythematosus.

02-01-2019 | Systemic lupus erythematosus | Highlight | News

Add-on omalizumab shows potential for SLE

Preliminary results from a phase Ib trial suggest that add-on treatment with the anti-IgE antibody omalizumab may be a feasible option for patients with systemic lupus erythematosus.

14-12-2018 | Pediatric | Article

Off-label use of tocilizumab to treat non-juvenile idiopathic arthritis in pediatric rheumatic patients: a literature review

Jung JY et al. Pediatr Rheumatol 2018; 16: 79. doi: 10.1186/s12969-018-0296-z

11-12-2018 | Systemic lupus erythematosus | Article

New therapeutic strategies in systemic lupus erythematosus management

Gatto M et al. Nat Rev Rheum 2018. doi: 10.1038/s41584-018-0133-2

Ustekinumab shows potential for the treatment of SLE

Ronald van Vollenhoven discusses phase II trial results demonstrating that the interkeukin-12/23 inhibitor ustekinumab may be a promising treatment option for systemic lupus erythematosus (5:36).

24-10-2018 | Systemic lupus erythematosus | ACR/ARHP 2018 | Video

Ustekinumab shows potential for the treatment of SLE

Ronald van Vollenhoven discusses phase II trial results demonstrating that the interkeukin-12/23 inhibitor ustekinumab may be a promising treatment option for systemic lupus erythematosus (5:36).

Vaccination in children and adolescents with rheumatic conditions

In this editorial, the authors discuss the risks of live vaccination in children taking antirheumatic medications and how to manage these, as well as how health authorities can address decreasing vaccination coverage of the general public.

18-10-2018 | Infection | Editorial | Article

Vaccination in children and adolescents with rheumatic conditions

In this editorial, the authors discuss the risks of live vaccination in children taking antirheumatic medications and how to manage these, as well as how health authorities can address decreasing vaccination coverage of the general public.

Planning and managing pregnancy in lupus patients

Megan Clowse discusses the importance of planning pregnancy in patients with lupus to avoid high-risk pregnancy, and outlines strategies to manage active lupus during pregnancy.

16-10-2018 | Pregnancy | Editorial | Article

Planning and managing pregnancy in lupus patients

Megan Clowse discusses the importance of planning pregnancy in patients with lupus to avoid high-risk pregnancy, and outlines strategies to manage active lupus during pregnancy.

15-09-2018 | Myositis | Review | Article

Current treatment for myositis

Barsotti S, Lundberg IE. Curr Treat Options in Rheum 2018. doi: 10.1007/s40674-018-0106-2

14-08-2018 | Lupus nephritis | Review | Article

Induction therapy for lupus nephritis: The highlights

Ayoub I, Nelson J, Rovin BH. Curr Rheumatol Rep 2018; 20: 60. doi: 10.1007/s11926-018-0766-9

06-08-2018 | Systemic sclerosis | News

Rituximab may improve lung, skin manifestations of SSc

Results of an open-label randomized trial suggest that rituximab may be an appropriate alternative to cyclophosphamide for treating lung and skin disease associated with systemic sclerosis.

26-07-2018 | Scleroderma | Article

Intravenous cyclophosphamide vs rituximab for the treatment of early diffuse scleroderma lung disease: Open label, randomized, controlled trial

Sircar G et al. Rheumatology (Oxford) 2018: key213. doi: 10.1093/rheumatology/key213

image credits